In vertebrates, GABA~A~Rs mediate both phasic and tonic neuronal inhibition in the adult central nervous system[@R1]--[@R3]. Their dysfunction leads to channelopathies associated with epilepsy, insomnia, anxiety and chronic pain[@R4]. GABA~A~Rs are among the most important human drug targets due to their many allosteric sites that bind compounds with anticonvulsant, anti-anxiety, analgesic, sedative and anaesthetic properties[@R5],[@R6]. Some of these, such as benzodiazepines (BZDs), typically positive allosteric modulators, entered clinical use decades before the identity of their receptors was known[@R7],[@R8] and were crucial for the isolation[@R9], and subsequent cloning[@R10], of GABA~A~Rs. Other GABA~A~R ligands are important research tools, including the antagonists picrotoxin (PTX) and bicuculine (BCC)[@R5],[@R6].

The binding modes and conformational impact of most GABA~A~R allosteric modulators are unknown. Docking attempts had to rely on models based on homologous proteins, including the *C. elegans* glutamate-gated chloride channel α (GluCl)[@R11], *Torpedo* nicotinic acetylcholine receptor[@R12] or the human homopentameric β3 GABA~A~R[@R13] structures, all distant from the physiological, heteromeric GABA~A~Rs. Crystallographic and single-particle cryo-EM studies have illustrated interactions of GABA~A~R-derived constructs with neurosteroids[@R14]--[@R16], the agonist GABA[@R17]--[@R19] and the BZD site ligands bretazenil (BRZ)[@R20], and flumazenil (FLZ)[@R18],[@R20]. However, the use of engineered receptors, in detergents micelles, limits the interpretability of such structures.

Functional studies on small molecule GABA~A~R modulators have also raised numerous conundrums. We will list here just a few examples. It is not known why the two agonist (GABA) binding sites, which should be structurally identical, are not functionally equivalent[@R21]. The mechanism of BZDs action is also unclear, despite their widespread use as sedatives and anxiolytics. Moreover, unlike newer compounds such as bretazenil and flumazenil mentioned above, classical BZDs including diazepam (DZP, Valium) and alprazolam (ALP, Xanax) act specifically through GABA~A~Rs containing α1/2/3/5, but not α4/6 subunit types[@R22],[@R23]. What is the basis for this specificity? The plant alkaloid PTX, one of the most widely used GABA~A~R antagonists[@R24], is believed to act as a channel blocker. However, its competitive antagonistic properties suggest that additional binding sites might exist[@R25],[@R26]. Another broadly used GABA~A~R antagonist, BCC, is thought to act competitively. However, the BCC preference to bind resting over desensitized receptors suggests that it might also act allosterically[@R27]. Where do important reagents like PTX and BCC actually bind, and how do they work?

To address these unknowns, here we present five structures of the human synaptic α1β3γ2L GABA~A~R in complex with PTX, PTX/GABA, BCC, DZP/GABA and APL/GABA, establishing the binding modes and structural impact of these ligands and explaining the molecular basis for their function. In order to obtain structures where GABA~A~R can be observed in more physiologically relevant conformations, we employed a full-length receptor variant, from a thoroughly characterised cell line[@R28] and reconstituted it in a lipid bilayer[@R29]. Our results lay the foundation for understanding the fundamental principles of small molecule action on heteromeric synaptic GABA~A~Rs.

Picrotoxin and GABA binding modes {#S1}
=================================

We first solved the structure of the α1β3γ2L receptor in complex with PTX (800 μM) to 3.1 Å nominal resolution ([Fig. 1a](#F1){ref-type="fig"}, [Extended Data Fig. 1a-f](#F6){ref-type="fig"}, [Extended Data Table 1](#T1){ref-type="table"}, [Supplementary Video 1](#SD3){ref-type="supplementary-material"}). PTX is an equimolar mix of two highly similar compounds, picrotin and picrotoxinin. Our structure illustrates picrotoxinin, known to be the more active one, fully sequestered in the channel pore between the M2 2′ and 9′ rings ([Fig. 1b-c](#F1){ref-type="fig"}, [Extended Data Fig. 1g](#F6){ref-type="fig"}, [Supplementary Video 2](#SD5){ref-type="supplementary-material"}). This agrees with mutagenesis and electrophysiology results implicating the 2′, 6′ and 9′ M2 residues in PTX binding[@R30]--[@R32] and suggestions that PTX becomes "trapped" in closed/resting GABA~A~R and GlyR channels upon agonist wash-off[@R33],[@R34]. The hydrophobic isoprenyl moiety is surrounded by the 9′ Leu ring, whereas the exocyclic oxygen atoms in the main PTX body form putative hydrogen bonds with the 6′ ring ([Fig. 1b, c](#F1){ref-type="fig"}). In picrotin, the isoprenyl group is replaced by a polar tertiary alcohol, not compatible with the 9′ Leu ring interactions, explaining why this compound is less active.

We next determined a GABA~A~R structure in complex with PTX (800 μM) and the neurotransmitter GABA (5 μM) to 3.04 Å nominal resolution ([Fig. 2a](#F2){ref-type="fig"}, [Extended Data Fig. 2a-c](#F7){ref-type="fig"}, [Extended Data Table 1](#T1){ref-type="table"}, [Supplementary Video 3](#SD6){ref-type="supplementary-material"}). The orthosteric GABA-binding sites are located at the two β3^+^/α1^--^ interfaces \[the principal (+) and complementary (--) annotation of subunit faces is used\], capped by the extracellular loops-C of the β subunits[@R18],[@R19],[@R29]. Reminiscent of the *Torpedo* nAChR α subunits[@R35], in the agonist-free GABA~A~R the β3 loops-C adopt "open" (outwards-projecting) conformations, whereas in the PTX/GABA-bound state they are "closed" ([Extended Data Fig. 2d](#F7){ref-type="fig"}). Strong EM densities are present in the two orthosteric ligand binding sites allowing unambiguous modelling of GABA molecules in the "aromatic boxes" formed by β3Tyr157, β3Phe200, β3Tyr205 and α1Phe65 ([Fig. 2b](#F2){ref-type="fig"}, [Extended Data Fig. 2e](#F7){ref-type="fig"}, [Supplementary Video 4](#SD7){ref-type="supplementary-material"}). The GABA amino group engages in a cation-π interaction with β3Tyr205 and a network of hydrogen bonds involving the β3Glu155 carboxyl, main chain carbonyls of β3Ser156 and β3Tyr157, and the β3Tyr97 hydroxyl. The GABA carboxylate forms salt bridges with α1Arg67 and hydrogen bonds with α1Thr130 and β3Thr202 ([Fig. 2b](#F2){ref-type="fig"}). The GABA binding modes we observe are generally consistent with those proposed in lower resolution α1β1γ2 and α1β2γ2 GABA~A~R models[@R18],[@R19], however there are differences in detail[@R29].

Allosteric cross-talk between PTX and GABA {#S2}
==========================================

Co-application of PTX (800 μM) with GABA (5 μM) and Mb38 (2 μM) causes rapid and complete inhibition of whole-cell currents in HEK293 cells, with complete recovery after PTX washout ([Extended Data Fig. 2f-h](#F7){ref-type="fig"}). Unexpectedly, in both PTX- and PTX/GABA-bound structures TMDs adopt the same conformation, where all five M2 helices present the hydrophobic 9′ Leu side chains towards the centre of the pore, constricting its radius to \~1.5 Å ([Fig. 2c](#F2){ref-type="fig"} and [Extended Data Fig. 2i](#F7){ref-type="fig"}). This suggests that PTX inhibition is not caused by blocking an open pore, but by inducing and maintaining a closed pore conformation. It is likely that, by stabilising the closed/resting TMD state, PTX affects the ECD conformation and impacts on agonist binding. Indeed, it has been shown that PTX reduced the apparent agonist affinity in GABA~A~Rs[@R26],[@R36] and increased GABA dissociation[@R37]. Therefore, TMD closure by PTX constitutes the basis for allosteric communication between the PTX and GABA binding sites and explains how PTX appears to act as a competitive inhibitor[@R34],[@R38],[@R39] without binding to other receptor pockets. We conclude that the PTX-bound structure best illustrates the α1β3γ2L receptor in a closed/resting state (closed TMD, agonist-free ECD).

Mechanistic impact of GABA binding {#S3}
==================================

Previous observations suggested that the two GABA binding sites may not be functionally equivalent[@R21],[@R40], and the β-E^+^/α-D^--^ site was estimated to have a threefold higher affinity for GABA than the β-B^+^/α-A^--^ one[@R21]. By comparing ECDs in the PTX- versus PTX/GABA-bound structures, both with closed-state TMDs, one could visualise the initial conformational changes at the two agonist binding sites upon GABA binding. Closure of β3 loops-C, likely the first step in the process, triggers remodelling of the β3-B^+^/α1-A^--^ and β3-E^+^/α1-D^--^ interfaces which leads to an anti-clockwise (looking down the pore axis from the extracellular space) asymmetric rotation of all subunit ECDs ([Fig. 2d](#F2){ref-type="fig"}). This state is stabilised by new hydrogen bond networks involving the β3Gly158, β3Tyr205 and α1Arg85 residues. The cation-π interaction between α1Arg85 and β3Tyr159 breaks and the α1Arg85 side chain moves to the periphery of the interface ([Fig. 2e, f](#F2){ref-type="fig"}). At the β3-B^+^/α1-A^--^ interface, these changes allow the β3-B subunit to move closer to the α1-A subunit by 1.5 Å as measured between β3Gly33C~α~ and α1Pro80C~α~, and the total buried surface between the two subunit ECDs increases by 184 Å ([Extended Data Fig. 2j](#F7){ref-type="fig"}, [Extended Data Table 2](#T2){ref-type="table"}). In the GABA-bound conformation, α1Phe15 and β3Phe31 residues form a hydrogen-π stacking interaction and the side chains of α1Arg85 and β3Asp163 form new salt bridges, further interlocking the β3-E^+^/α1-D^--^ ECD interface and increasing its total buried surface area by 234 Å ([Fig. 2f](#F2){ref-type="fig"}, [Extended Data Table 2](#T2){ref-type="table"}, [Supplementary Video 5](#SD8){ref-type="supplementary-material"}).

The "incomplete" β3-B^+^/α1-A^--^ interface closure in the PTX/GABA-bound structure, relative to β3-E^+^/α1-D^--^, delineates an intermediate conformation from which GABA can presumably dissociate more readily. Interestingly, in the desensitised (high affinity to GABA[@R41]) receptor states, described later in this paper, both β3^+^/α1^--^ interfaces close to the same degree. We conclude that the PTX/GABA-bound structure represents a pre-active receptor state, where agonist induced conformational changes at the ECD level are not large enough to perturb the closed/resting TMD conformation[@R42].

Mechanism of bicuculline antagonism {#S4}
===================================

A highly efficient competitive antagonist, BCC was expected to induce a bona fide GABA~A~R closed state[@R43]. We first verified whether BCC could close the α1β3γ2L receptor pre-bound to Mb38. In whole-cell voltage-clamp experiments, application of a 42 second pulse of Mb38 produced currents ([Fig. 3a](#F3){ref-type="fig"}) that were inhibited (102 ± 7 %; n = 4) by co-application of bicuculline (100 μM) ([Fig. 3b](#F3){ref-type="fig"}) in a reversible fashion ([Fig. 3c](#F3){ref-type="fig"}). We solved the cryo-EM structure of the α1β3γ2L heteromer in complex with Mb38 and BCC to 3.69 Å nominal resolution ([Fig. 3d](#F3){ref-type="fig"}, [Extended Data Fig. 3a-c](#F8){ref-type="fig"}, [Extended Data Table 1](#T1){ref-type="table"}). EM densities corresponding to BCC were observed at both orthosteric agonist sites ([Extended Data Fig. 3d](#F8){ref-type="fig"}), where the hydrophobic nature of its phthalide and isoquinoline rings allows it to interact with "aromatic box" residues β3Tyr157, β3Phe200, β3Tyr205 and α1Phe65 ([Fig. 3e](#F3){ref-type="fig"}, [Supplementary Video 6](#SD9){ref-type="supplementary-material"}). Relative to the PTX-bound structure, the β3-B and β3-E subunit loops-C flex inward, \~2.2 Å at the tip ([Extended Data Fig. 3e](#F8){ref-type="fig"}), to accommodate BCC, but retain overall "open" conformations ([Extended Data Fig. 3f](#F8){ref-type="fig"}). The channel pore of the BCC-bound α1β3γ2 receptor is fully closed by the M2 residues at three levels, 9′, -2′ and 2′ ([Fig. 3f](#F3){ref-type="fig"}) and its subunit conformations are virtually identical to the PTX-bound structure ([Extended Data Fig. 3e, f](#F8){ref-type="fig"}). BCC binding to the orthosteric sites prevents closure of the β3^+^/α1^--^ subunit interfaces and ECD rotation, and stabilizes TMDs in the closed/resting state, thus inactivating the channel.

Benzodiazepine binding modes and mechanisms {#S5}
===========================================

We next solved cryo-EM structures of the α1β3γ2L receptor in complex with GABA and ALP, as well as GABA and DZP, to 3.26 Å and 3.58 Å nominal resolutions, respectively ([Fig. 4a-c](#F4){ref-type="fig"}, [Extended Data Figure. 4a-f](#F9){ref-type="fig"}, [Extended Data Table 1](#T1){ref-type="table"}, [Supplementary Video 7](#SD10){ref-type="supplementary-material"}). In both structures, GABA molecules are bound to the orthosteric agonist pockets and ALP/DZP occupy the canonical BZD binding site at the α1+/γ2^--^ interface, where they form extensive interactions ([Fig. 4d-e](#F4){ref-type="fig"}). Densities for ALP and DZP are well defined, allowing us to distinguish the fused benzene-diazepine from the pendant phenyl rings ([Extended Data Figure. 4g-h](#F9){ref-type="fig"}, [Supplementary Video 8](#SD11){ref-type="supplementary-material"}).

The ALP/DZP binding modes are in agreement with the cysteine crosslinking experiments where isothiocyanate substitutions in the DZP C(7) position reacted with cysteines introduced at the α1His102, α1Asn103, γ2Asn60 positions and the DZP C(3) ones reacted with the α1Ser206Cys and α1Thr207Cys mutants[@R44]. The chlorine atoms at the C(8) and C(7) positions in ALP and DZP, respectively, interact with the α1His102 side chain. In α4/6 subunits the equivalent positions are occupied by arginine residues, whose larger side chains would sterically clash with ALP and DZP. This can explain why classical BZDs do not act on GABA~A~R subtypes containing α4/6 subunits[@R22],[@R45],[@R46]. The ALP and DZP-bound structures also demonstrate that BZDs with a pendant phenyl ring do not share the binding mode reported for the benzodiazepine antagonist FLZ and partial agonist BRZ[@R18],[@R20] ([Extended Data Fig. 5a-e](#F10){ref-type="fig"}). FLZ/BRZ bind deeper and higher from the BZD pocket floor delineated by the side chain of γ2Asn60, possibly due to additional hydrogen bonds between the imidazole nitrogen and ester carbonyl of FLZ/BRZ (both groups are absent in ALP/DZP structures) and the hydroxyl group of γ2Thr142[@R20] ([Extended Data Fig. 5c, e](#F10){ref-type="fig"}).

In the DZP/GABA-bound map, we also observed two strong EM densities in the putative general anaesthetic binding sites at the β3^+^/α1^--^ TMD interfaces[@R47] ([Extended Data Figure. 4i](#F9){ref-type="fig"}, [Supplementary Video 9](#SD12){ref-type="supplementary-material"}). These are not present in the ALP/GABA-bound map and have a distinct shape attributable to DZP. In these pockets, the DZP A ring forms hydrophobic interactions with β3Met286 and β3Phe289 and the phenyl ring points towards α1Pro233 ([Fig. 4f](#F4){ref-type="fig"}, [Extended Data Figure. 4i](#F9){ref-type="fig"}). Our structure validates previous electrophysiology and mutagenesis data suggesting the existence of secondary DZP binding sites, responsible for the anaesthetic activity and biphasic GABA~A~R potentiation at higher DZP concentrations[@R40],[@R48].

We next compared the α1^+^/γ2^--^ interfaces in PTX-, PTX/GABA-, BCC-, ALP/GABA- and DZP/GABA-bound structures. Surprisingly, ALP or DZP binding induced only minor rearrangements in the BZD pocket: γ2Asn60 adopted a different rotamer ([Extended Data Fig. 5f](#F10){ref-type="fig"}) and the tip of α1 loop-C flexed outwards \~0.6Å ([Extended Data Fig. 5f, g](#F10){ref-type="fig"}). We thus propose that BZDs such as ALP and DZP act as "connectors" to stabilize the weakest ECD interface, α1-D^+^/γ2-C^--^ ([Extended Data Table 2](#T2){ref-type="table"}), and facilitating the concerted ECD rotation upon GABA binding. Nb38 and Mb38 might act similarly by "crosslinking" the α1-A^+^/β3-E^--^ and α1-D^+^/γ2-C^--^ interfaces[@R20],[@R29]. FLZ antagonizes classical BZDs by competing for the same pocket but, since it interacts largely with the α1-D^+^ face[@R18],[@R20], its binding would not confer the same inter-subunit connectivity benefits ([Extended Data Fig. 5b, c](#F10){ref-type="fig"}).

The channel pore radii in ALP/GABA and DZP/GABA-bound structures are 2.6 Å and 2.3 Å, respectively, at the 9′ level, further constricted to 1.6 Å and 1.8 Å by the -2′ residues ([Fig. 4g](#F4){ref-type="fig"}). Whole-cell voltage-clamp experiments indicate that a prolonged exposure to a combination of GABA (10 mM), Mb38 (2 μM), and diazepam (100 μM) leads to the complete desensitization of the α1β3γ2L receptor ([Fig. 4h](#F4){ref-type="fig"}). Subunit comparison between ALP/GABA and DZP/GABA-bound structures reveals that they adopt similar conformations ([Extended Data Fig. 6](#F11){ref-type="fig"}), illustrating a desensitized state of the receptor, bound to agonist but with the channel closed only at the -2′ gate ([Supplementary Video 7](#SD10){ref-type="supplementary-material"}).

Allosteric interactions between ECDs and TMDs {#S6}
=============================================

To understand how the GABA-induced ECD rotation induces conformational changes in the TMD region, we compared ALP/GABA- and PTX-bound structures ([Fig. 5a,b](#F5){ref-type="fig"}). In the presence of ALP, GABA binding leads to equal closure of both β3+/α1^--^ interfaces and a larger ECD rotation compared to the pre-open PTX/GABA-bound structure ([Fig. 5a](#F5){ref-type="fig"}, [Extended Data Fig. 2j, k](#F7){ref-type="fig"}, [Extended Data Fig. 7a, b](#F12){ref-type="fig"}, [Supplementary Video 10](#SD4){ref-type="supplementary-material"}). This ECD conformational change triggers an anti-clockwise TMD rotation. The resulting tilt of M2 helices moves the 9′ Leu side chains away from the channel pore and towards the inter-subunit interfaces ([Fig. 5b](#F5){ref-type="fig"}, [Extended Data Fig. 7c](#F12){ref-type="fig"}). These motions are transmitted through interactions between the β1-β2 and M2-M3 loops, whereas the β6-β7 (Cys) loops act as pivot points and the TMD bundles rotate as rigid bodies ([Extended Data Fig.7d](#F12){ref-type="fig"}, [Extended Data Fig. 8a-f](#F13){ref-type="fig"}, [Supplementary Video 10](#SD4){ref-type="supplementary-material"}).

The relative flexibility in M2-M3 loops appears to regulate the ECD-TMD signal transduction efficiency. In α1 and γ2 subunits, the highly conserved Arg residues at the M2 19′ positions interact with and rigidify the M2-M3 loops. However, in β3 subunits, the strictly conserved Lys279 residues displace the 19′ Arg269 side chains, causing them to rotate and wedge in between the M1 and M2 helices of the neighbouring α1 subunits. This restricts the β3 TMD rotations ([Extended Data Fig. 8g-l](#F13){ref-type="fig"}), possibly dampening signal transduction. In α1 and γ2 subunits, positions equivalent to β3Lys279 are occupied by conserved Thr residues which do not clash with 19′ Arg ([Extended Data Fig. 8g-l](#F13){ref-type="fig"}). The β3 M2-M3 loops appear therefore more flexible than α1 and γ2 ones ([Extended Data Fig. 7d](#F12){ref-type="fig"}, [Supplementary Video 10](#SD4){ref-type="supplementary-material"}). In agreement with these observations, α1β3γ2L receptors containing β3Lys279Thr mutations are 20-fold more sensitive to GABA relative to wild-type ones[@R49].

We propose that GABA-induced signalling can be described by a "lock and pull" mechanism. GABA binding triggers loops-C closure in β subunits, initiating their ECD rotation and "locking" them to the neighbouring α^--^ interfaces. These conformational changes "pull" the other ECDs, leading to a concerted anti-clockwise rotation. Inclusion of a BZDs strengthens the α1^+^/γ2^--^ ECD interface to facilitate these motions ([Fig. 5c](#F5){ref-type="fig"}). In β subunits, signal transduction to TMDs is modulated by the flexible M2-M3 loops, whereas the ECD rotations of α and γ subunits couple to the TMDs more efficiently, as their M2-M3 loops are more rigid ([Fig. 5d](#F5){ref-type="fig"}).

Conclusion {#S7}
==========

The structures presented here illustrate how important pharmacological compounds, used broadly in research and clinic, interact with a full-length human heteromeric GABA~A~R to modulate its conformation and function. Picrotoxin must initially bind to an open channel pore and subsequently stabilises a closed/resting receptor state, which explains its simultaneous channel blocker and allosteric antagonist activities. Bicuculline occupies the agonist-binding sites. However, unlike GABA, it cannot drive the rotation of β subunits and therefore stabilizes the closed channel pore. Comparison of agonist-free and GABA-bound structures delineates the molecular mechanism by which neurotransmitter binding to the β3^+^/α1^--^ interfaces prompts a global rotation of ECD regions, initially in an asymmetrical fashion, and explains how different subunit types transduce this conformational change to their TMDs. We also characterise the binding sites of two major classical benzodiazepines, alprazolam and diazepam, and define their primary role as stabilizers of the α^+^/γ^--^ interface, facilitating the concerted motion of GABA~A~R subunits. This work underlines the potential of cryo-EM to study drug interactions with challenging yet highly valuable human membrane protein targets[@R50]. Specifically, these structures might lead to the rational design of safer and more specific anxiolytic, sedative, hypnotic and anticonvulsant drugs.

Methods {#S8}
=======

GABA~A~ receptor production, purification and nanodisc reconstitution {#S9}
---------------------------------------------------------------------

Human tri-heteromeric α1β3γ2L was expressed in a stable, doxycycline-inducible HEK293S-TetR cell line[@R28] grown in suspension. The cell line was not authenticated or tested for mycoplasma contamination. The receptor comprised the full-length human α1 (UniProtKB P14867), β3 (P28472) and γ2L (P18507) subunits, each under individual antibiotic selection (zeocin, hygromycin-B, geneticin/blasticidin, respectively). For quality control and purification, a FLAG tag (DYKDDDDK)[@R51] was fused to the α1 subunit N-terminus and a Rhodopsin-1D4 tag (TETSQVAPA)[@R52] was fused to the γ2L subunit C-terminus, downstream of a (GGS)~3~GK spacer sequence. Cells were grown in FreeStyle 293 expression medium (Gibco) supplemented with 1% fetal bovine serum (Invitrogen), and antibiotics for selection (geneticin, hygromycin-B, zeocin and blasticidin, Thermo Fisher Scientific) at 37 °C, 160 rpm, 8% CO~2~. GABA~A~R expression was induced by the addition of doxycycline (2 μg ml^-1^, Sigma) at a cell density of \~2×10^6^ cells ml^-1^. At the same time, the medium was supplemented with 5mM sodium butyrate and the class I α-mannosidase inhibitor kifunensine (1 mg l^-1^, Toronto Research Chemicals), in order to boost recombinant protein yields. Due to this treatment, the majority of N-linked glycans were restricted to the immature, ER-type Man~9~GlcNAc~2~. Cells were harvested by centrifugation \~24 h after doxycycline addition. All steps of purification were performed at 4°C or on ice. Cell pellets from 0.4 l of suspension culture were resuspended by brief vortexing in dilution buffer (50mM HEPES pH 7.6, 300mM NaCl) supplemented with 1 % (v/v) mammalian protease inhibitor cocktail (Sigma-Aldrich). Membrane proteins were solubilised with 1% (v/v) n-dodecyl β-D-maltopyranoside (DDM, Anatrace; used for BCC- and DZP/GABA-bound samples) or lauryl maltose neopentyl glycol (LMNG, Anatrace; used for PTX-, PTX/GABA-, ALP/GABA-bound samples) with cholesterol hemisuccinate (CHS, Anatrace) at a 10:1 molar ratio, respectively, for 1 h. Insoluble material was removed by centrifugation (10,000 g, 30 min). The α1β3γ2 GABA~A~Rs in the supernatant were captured on 1D4 affinity resin[@R13] (300 μl) while mixing slowly for 2 h. The beads were recovered by centrifugation (300 g, 5 min) and washed with 100 ml of dilution buffer supplemented with 0.1% (v/v) DDM:CHS (10:1) or LMNG:CHS (10:1). To reduce the time α1β3γ2 GABA~A~R spends solubilised in detergent, and to streamline protein specimen preparation for cryoEM, we reconstituted the α1β3γ2 heteromer into nanodiscs while it was bound to the 1D4 beads. Receptors were equilibrated with 1 ml of dilution buffer containing an excess (40 μl) of a phosphatidylcholine (POPC, Avanti) and bovine brain lipid (BBL) extract (Type I, Folch fraction I, Sigma-Aldrich) mixture (POPC:BBL=85:15) for 30 min. POPC and BBL extract stocks (10 and 20 mg ml^-1^, respectively) were prepared by solubilisation in 3% DDM. Beads were collected by centrifugation and an excess of MSP2N2 (0.6 mg ml^-1^ final concentration) was added together with Bio-Beads (40 mg ml^-1^ final concentration) and incubated for 2 h rotating gently. The MSP2N2 belt protein was produced as previously described[@R53]. After nanodisc reconstitution, the 1D4 resin and Bio-Bead mixture was washed extensively with dilution buffer to remove empty nanodiscs. For protein elution, 100 μl of mixture containing 1 part of dilution buffer and 3 parts of 2 mM 1D4 peptide stock (in MilliQ-grade H~2~O) was added onto the 1D4 resin for incubation overnight. The next day, beads were settled down by a short centrifugation (300 g, 5 min) and the eluate was collected. Typically, the eluate contains 0.1--0.25 mg ml^-1^ of α1β3γ2 heteromer, which was then directly used for cryo-EM grid preparation.

Mb38 production and purification {#S10}
--------------------------------

Megabodies (Mbs) are chimeric proteins comprised of Nanobodies (Nbs) fused to larger scaffold proteins (to be published elsewhere). A circular permutant of the extracellular adhesin domain of *H. pylori* (HopQ)[@R54] was inserted into the first β-turn connecting β-strands A and B of anti-α1 subunit Nb38[@R20] resulting in monomeric $\text{M}\text{b}_{\text{Nb}38}^{\text{cHopQ}}$ (\~58 kDa). $\text{M}\text{b}_{\text{Nb}38}^{\text{cHopQ}}$ was expressed as a C-terminally His6-tagged periplasmic protein in *E. coli* WK6 cells. Cell cultures were grown at 37 °C (120 rpm) in Terrific Broth medium supplemented with ampicillin to an optical density of 0.8 at 600 nm followed by induction with 1mM IPTG and overnight expression 28 °C (120 rpm). $\text{M}\text{b}_{\text{Nb}38}^{\text{cHopQ}}$ was extracted from periplasm by osmotic shock[@R55], and further purified using nickel affinity chromatography and size-exclusion chromatography (Superdex 200 16/60 column, GE Healthcare) in 10 mM Tris pH 7.3, 140 mM NaCl at 21 °C. Purified $\text{M}\text{b}_{\text{Nb}38}^{\text{cHopQ}}$ was concentrated to \~15 mg ml^-1^, frozen in liquid nitrogen and stored at -80 °C.

Cryo-EM sample preparation {#S11}
--------------------------

α1β3γ2L heteromeric receptors reconstituted into nanodiscs were supplemented with small molecule compounds at the concentrations indicated in the main text, and with Mb38 (1-2 μM) to improve particle alignment and the proportion of side views in cryoEM images. 3.5 μl of sample was applied onto glow-discharged gold R1.2/1.3 300 mesh UltraAuFoil grids (Quantifoil) for 30 s and then blotted for 5.5 s before plunge-freezing the grids into liquid ethane cooled by liquid nitrogen. Plunge-freezing was performed using a Vitrobot Mark IV (Thermo Fisher Scientific) at \~100% humidity and 14.5°C.

Cryo-EM image collection and processing {#S12}
---------------------------------------

Cryo-EM data were collected on a 300 kV Titan Krios microscopes (Thermo Fisher Scientific) fitted with a GIF-Quantum energy filter (Gatan) and Volta Phase Plate (VPP, Thermo Fisher Scientific). Micrographs were recorded in counting mode using K2 Summit (Gatan) or Falcon 3EC (Thermo Fisher Scientific) direct electron detectors. For sample-specific data collection parameters, see [Extended Data Table 2](#T2){ref-type="table"}.

Datasets were analysed using the same basic processing pipeline in RELION 3.0[@R56] as described below. First, MotionCor2[@R57] and Gctf[@R58] wrappers in RELION 3.0 were used to motion-correct movies, and to estimate the contrast transfer function (CTF) and phase shift parameters, respectively. Poor quality images were discarded after manual inspection. For particle picking, a Gaussian blob was used as a template to auto-pick particles from a small set of micrographs and 2D classification was performed. Selected 2D classes were used as templates for auto-picking particles from all micrographs. Two rounds of reference-free 2D classifications were performed and well-aligned 2D classes showing clear GABA~A~R projections were selected for 3D reconstruction. An initial reference-free 3D model was generated in RELION 3.0 using stochastic gradient descent (SGD) methodology[@R59]. Selected particles were 3D-refined ('gold standard' refinement) and Bayesian polishing of particles was performed[@R60]. Next, the polished particles were classified into eight 3D volumes without particle alignment. Particles from volumes with the highest resolution were combined and 3D-refined using a soft mask and solvent-flattened FSCs. Beam tilt correction and per-particle CTF refinement implementations in RELION 3.0 were applied, resulting in further 0.1--0.2 Å increase in resolution. Most notably, for the DZP/GABA-bound GABA~A~R dataset, beam tilt correction helped increase the resolution from 3.82 Å to 3.58 Å. The resolution was estimated using *relion_postprocess* with the FSC criteria of 0.143. Local map resolution was estimated with MonoRes[@R61].

The initial atomic model used in this work was obtained from the truncated α1β3γ2 heteromer structure[@R20]. First, ECDs and TMDs from this model were fit to the PTX/GABA-bound α1β3γ2 heteromer map (3.04 Å nominal resolution) as rigid bodies using UCSF Chimera[@R62]. COOT[@R63] was used to adjust the model and build the regions absent in the truncated receptor form. The model was then subjected to several rounds of global refinement and minimisation in real space using *phenix_real_space_refine*[@R64]. The resulting model served as a starting point for the other structures, applying the same refinement strategy. The geometry constraint files for small molecule ligands used in the refinement were generated using the Grade Web Server (Global Phasing Ltd.). The quality assessment of geometry in all models was performed using the MolProbity[@R65] Web Server. For the refinement protocol validation, each final model coordinates were displaced by 0.5 Å and refined using *phenix_real_space_refine* against one of each half-map sets produced by RELION 3.0. FSC curves were then calculated between this model and the half-map used for refinement ('work') and the half-map, which was not used for refinement, ('free') using *phenix.mtriage*[@R66]*.* In addition, the refined models were also compared against the final sharpened map ('full'). For all structures, the separation between FSC~work~ and FSC~free~ curves was not significant, indicating that the models were not over-refined.

Subunit interface surface and associated free energy parameter analysis was performed using the PDBePISA server[@R67]. Pore diameters were calculated using the HOLE[@R68] plug-in in COOT. Structural figures were prepared using UCSF Chimera[@R62]. Global TMD alignments were performed using the *align* command in PyMol (Schrödinger, LLC). TMD boundaries for global alignments: α1 residues 233-309 and 392-418, β3 residues 218-302 and 419-447, γ2 residues 233-319 and 411-436. ECD alignments were performed using the *match* command in UCSF Chimera. ECD boundaries for structural alignments: α1 residues 9-222, β3 residues 8-217, γ2 residues 26-232. Root mean square deviations (RMSD) were calculated using the *rmsd* function in UCSF Chimera. M2-M3 loop boundaries for RMSD calculations: α1 residues 276-284, β3 residues 271-279, γ2 residues 286-294. Rotation angles were calculated using UCSF Chimera.

Electrophysiology {#S13}
-----------------

HEK 293S cells producing α1β3γ2L receptors[@R28], were grown on glass coverslips, and expression was induced with 0.1-2 μg ml^-1^ doxycycline for 14 to 28 hours depending on the level of current required. For pulling outside-out macro-patches, we used poly-L lysine coated glass coverslips (Becton Dickinson, Franklin Lakes, NJ). Cells were also treated with kifunensine (5 μg ml^-1^) at the time of induction.

Currents were recorded in either whole-cell or outside-out configuration of patch clamp using an Axopatch 200A amplifier (Molecular Devices, San Jose, CA). Ligands were applied via a quad-channel super-perfusion pipette coupled to a piezoelectric element that switched the super-perfusion solution in \<1 ms as described previously[@R69]. Data were acquired using Clampex 8.2 (Molecular Devices, San Jose, CA). For short drug applications, data were acquired at 10 kHz and filtered at 5 kHz, whereas for longer applications, data were collected at 2 kHz and filtered at 1 kHz. Cells or patches were continually perfused with a bath solution consisting of (in mM): 145 NaCl, 5 KCl, 10 HEPES, 2 CaCl2, 1 MgCl2 and 10 glucose, pH 7.4 (adjusted with NaOH). The pipette solution consisted of (in mM): 140 KCl, 10 HEPES, 1 EGTA, 2 MgCl2 and 2 Mg-ATP, pH 7.3 (adjusted with KOH). For whole-cell recordings, the open pipette resistances ranged from 1.3 -- 2.5 MΩ and for outside-out patches 6 --10 MΩ. For whole-cell recordings, cell capacitance ranged from 5 -- 13 pF and series resistance ranged from 0.2 -- 2.5 MΩ. Series resistances were electronically compensated by \<85% with a lag of 10 μs. Cells and patches were voltage-clamped at --52 mV unless otherwise stated. The liquid junction potential of --2 mV between the bath and pipette solution was corrected post-recordings.

Electrophysiology Data Analysis {#S14}
-------------------------------

Clampfit 9 (Molecular Devices, San Jose, CA) was used to measure the peak current amplitudes. Current traces were normalized and prepared for presentation in Origin 6 (OriginLab Corporation, Northampton, MA). All data are presented as mean ± S.D. Statistical analysis was done using Prism 6 (Graphpad Software, La Jolla, CA).

Materials {#S15}
---------

All reagents for electrophysiology solutions were purchased from either Millipore Sigma (Burlington, MA) or ThermoFisher Scientific (Waltham, MA). Diazepam, doxycycline and DMSO were purchased from Millipore Sigma (Burlington, MA). Bicuculline and Kifunensine were purchased from Tocris (Pittsburg, PA). A stock solution of bicuculline (100 mM) was prepared fresh each day in DMSO. The stock solution of diazepam (500 mM) in DMSO was stored at -80°C. A working solution of diazepam (100 μM) in the bath solution was prepared fresh daily and was dissolved by sonication. In control experiments, patches exposed to GABA (10 mM) in the presence of DMSO (0.02% used in application of diazepam) did not differ from those exposed to GABA (10 mM) alone. The small Mb38 elicited currents were enhanced by a similar small amount by 0.1% DMSO (84 ± 41% (n = 3).

Extended Data {#S16}
=============

![Single particle cryo-EM analysis of human α1β3γ2L GABA~A~R bound to the channel blocker picrotoxin (PTX).\
**a,** Representative micrograph of the PTX-bound GABA~A~R particles embedded in vitreous ice. **b,** Representative 2D class averages. **c,** FSC curves for the 3D reconstruction using gold-standard refinement in RELION[@R56]. Curves shown for the phase randomisation, unmasked maps, masked and phase-randomisation corrected masked maps. **d,** Validation of model refinement: model versus summed map (FSC~full~), model refined in half-map 1 versus half-map 1 (FSC~work~), model refined in half-map 1 versus half-map 2 (FSC~free~). **e,** The final, unsharpened cryo-EM map coloured by local resolution (estimated using MonoRes[@R61]) shown at a higher contour level (left) and at a lower level (right) to highlight the nanodisc belt and flexible intracellular domains (ICDs). **f,** Angular distribution of particle projections. The map of GABA~A~R-PTX complex is shown in teal. **g**, Cryo-EM density segments for the PTX binding site between residues 2\' and 9\' of the M2 transmembrane helices.](emss-80639-f006){#F6}

![Structural and electrophysiological analyses of human α1β3γ2L GABA~A~R in complex with PTX and GABA.\
**a,** FSC curves for the 3D reconstruction of the GABA~A~R bound to PTX and GABA. Curves shown for the phase randomisation, unmasked maps, masked and phase-randomisation corrected masked maps. **b,** Validation of the model refinement protocol. Curves shown for model versus summed map (FSC~full~), model refined in half-map 1 versus half-map 1 (FSC~work~), model refined in half-map 1 versus half-map 2 (FSC~free~). **c,** The final, unsharpened cryo-EM map coloured by local resolution (estimated using MonoRes[@R61]). **d,** Superposition of the PTX- and PTX/GABA-bound α1β3γ2 receptor based on the global TMD alignment. The GABA-induced movements of loop-C in each of the of β3 subunits are highlighted by green lines between C~α~ atoms of Thr202 residues. GABA is shown as spheres (carbon atoms in khaki; nitrogen, blue; oxygens, red). **e,** Cryo-EM density segments showing GABA binding sites the PTX/GABA-bound structure. **f-h,** Representative whole-cell current traces elicited from the same HEK cell by three 8.8 s pulses of GABA (5 μM) plus Mb38 (2 μM) each separated by a 1 min wash: **(f)** Control; **(g)** one second after the start of the second 8.8 s pulse, PTX (800 μM) was co-applied for 4 s; **(h)** wash control showing full recovery. PTX inhibited currents by 106 ± 2.6 % (mean ± S.D.; n= 6 cells). In addition, the protocol was repeated with outside--out patches (117 ± 9 % (mean ± S.D.; n = 5 patches). **i,** Globally superposed PTX- and PTX/GABA-bound α1β3γ2 receptor transmembrane domains viewed from the extracellular space. Side chains of 9\' Leu residues are shown as sticks, whereas PTX is represented as balls and sticks. **j**, **k,** Superposition of α1 subunit ECDs from PTX-bound and PTX/GABA-bound α1β3γ2 receptors reveal the relative β3 ECD motions towards α1 ECDs, as viewed from outside of the receptor **(j)** and from the vestibule **(k)**. Differences of distances (Å) between the selected C~α~ atoms in the complexes without and with GABA are indicated by lines. The PTX-bound structure is shown in grey and the PTX/GABA-bound structure is coloured by subunit (α1, red; β3, blue; γ2, yellow).](emss-80639-f007){#F7}

![Structural analysis of human α1β3γ2L GABA~A~R bound to the competitive antagonist bicuculline (BCC).\
**a,** FSC curves for the 3D reconstruction of the GABA~A~R bound to BCC. Curves shown for the phase randomisation, unmasked maps, masked and phase-randomisation corrected masked maps. **b,** Validation of the model refinement protocol. Curves shown for model versus summed map (FSC~full~), model refined in half-map 1 versus half-map 1 (FSC~work~), model refined in half-map 1 versus half-map 2 (FSC~free~). **c,** The final, unsharpened cryo-EM map coloured by local resolution (estimated using MonoRes[@R61]). **d,** Cryo-EM density maps of the BCC-binding pockets. **e,** Superposition of the PTX- and BCC-bound α1β3γ2 receptor based on the global TMD alignment. The BCC-induced movements of loop-C in each of the β3 subunits are highlighted by green lines between C~α~ atoms of Thr202 residues. BCC is shown as spheres (carbon atoms in khaki; nitrogen, blue; oxygens, red). **f,** Superposition of individual subunits from the PTX- and BCC-bound GABA~A~R structures. Root mean square deviation (RMSD) values (Å) for equivalent C~α~ in the entire subunits are shown. Loops-C are marked by arrows. The PTX-bound structure is shown in grey and the BCC-bound structure is coloured by subunit (α1, red; β3, blue; γ2, yellow).](emss-80639-f008){#F8}

![Structural analysis of human α1β3γ2L GABA~A~R in complexes with alprazolam (ALP) and diazepam (DZP).\
**a,** FSC curves for the 3D reconstruction of the GABA~A~R bound to ALP. Curves shown for the phase randomisation, unmasked maps, masked and phase-randomisation corrected masked maps. **b,** Validation of the model refinement protocol. Curves shown for model versus summed map (FSC~full~), model refined in half-map 1 versus half-map 1 (FSC~work~), model refined in half-map 1 versus half-map 2 (FSC~free~). **c,** The final, unsharpened cryo-EM map coloured by local resolution (estimated using MonoRes[@R61]). **d-f,** same as **a-c** but for the GABA~A~R bound to diazepam (DZP). **g-i,** Cryo-EM density maps of the ligand binding sites: ALP binding in benzodiazepine (BZD) pocket (**g**), DZP binding in the BZD pocket (**h**), DZP binding in the general anaesthetic pocket at the β3^+^/α1^--^ interface (**i**). Ligands are shown in sticks, ALP carbon atoms coloured in blue, DZP carbon atoms coloured in teal, nitrogens in blue and chlorine atoms in green. Side chains of residues lining the binding pockets are shown as sticks and are numbered. Dotted circles highlight the difference between the structures of alprazolam and diazepam.](emss-80639-f009){#F9}

![Classical benzodiazepines, flumazenil and bretazenil bind to the same BZD pocket in GABA~A~Rs, but use different modes.\
ALP/GABA- and DZP/GABA-bound structures are coloured by subunit (α1, red; β3, blue; γ2, yellow), whereas the other superposed structures are shown in grey. Loop-C is in coil representation, to allow better visualization of the benzodiazepine (BZD) pocket. **a,** Structural formulae of flumazenil (FZL) and (S)-bretazenil (BRZ). **b**, **c,** Superposition of γ2 subunit ECDs from the DZP-bound α1β3γ2 and FZL-bound α1β2γ2 receptor structures reveals the FZL[@R16] (white) position in the BZD pocket relative to DZP (teal). Side-on (**b**) and top-down views (**c**) of the pocket are presented. **d, e,** the same as for **b, c** but the structural alignment shows the relative position of the BRZ[@R15] (white). Grey dashed lines indicate hydrogen bonds FZL and BRZ form with γ2Thr142 in the BZD pocket. **f,** Superposition of γ2 subunit ECDs from the PTX-, PTX/GABA-, BCC-, DZP/GABA- to ALP/GABA-bound γ2 ECD illustrates BZD pocket conformational changes associated with ALP/DZP binding: (i) an outward movement of loop-C; (ii) rearrangement of γ2Tyr58 and γ2Phe77 side chains, and (iii) change of the γ2Asn60 rotamer. **g,** Superposition of the α1-D subunit ECDs from the PTX-bound and ALP/GABA-bound α1β3γ2 structures shows that ALP binding causes only a minimal outwards motion of the α1 loop-C, by 0.8 Å as measured between Ser206 C~α~ atom positions.](emss-80639-f010){#F10}

![Superimposition of individual subunits from ALP- and DZP-bound α1β3γ2L GABA~A~R structures.\
Superposition of the individual subunits from the DZP- (grey) and ALP-bound (α1, red; β3, blue; γ2, yellow) GABA~A~R structures. Root mean square deviation (RMSD) values are in the 0.38-0.41 Å range for α1 (343-344 equivalent C~α~ positions), 0.37-0.40 Å for β3 (334-336 equivalent C~α~ positions) and 0.47 Å for γ2 subunits (330 equivalent C~α~ positions). Loops-C are marked by arrows.](emss-80639-f011){#F11}

![Structural analysis of PTX- and ALP/GABA-bound α1β3γ2L GABA~A~R structures.\
The PTX-bound structure is shown in grey and the ALP/GABA-bound structure is coloured by subunit (α1, red; β3, blue; γ2, yellow). **a**, **b,** Superposition of α1 subunit ECDs from PTX-bound and ALP/GABA-bound GABA~A~Rs reveals the relative β3 ECD motions towards α1 ECDs, as viewed from outside of the receptor **(a)** and from the vestibule **(b)**. Differences in distances (Å) between the selected C~α~ atoms in the complexes without and with GABA are indicated with lines. **c,** Individual subunits from the PTX- and ALP/GABA-bound GABA~A~R structures superposed based on the global TMD alignment (ALP/GABA TMD over PTX TMD). Angles between vectors representing M2 helices and the pore axis of the PTX-bound structure are shown. Side chains of residues at -2′ and 9′ positions are shown. **d,** Superposition of TMDs from PTX- and ALP/GABA-bound structures. RMSD values (Å) are shown for entire TMDs and for the M2-M3 loops (see [Methods](#S8){ref-type="sec"} for boundary definitions).](emss-80639-f012){#F12}

![Conformational differences at the ECD-TMD interfaces between PTX-bound (closed) and ALP/GABA-bound (desensitised) α1β3γ2L GABA~A~R structures.\
The PTX-bound structure is shown in grey and the ALP/GABA-bound structure is coloured by subunit (α1, red; β3, blue; γ2, yellow). The TMDs of the principal subunits of PTX-bound and ALP/GABA-bound structures were superposed allowing visualisation of relative movements of neighbouring ECDs and TMDs. **a, b,** Structural rearrangements of the ECD--TMD interface between α1-A and β3-E subunits. **c, d,** the same as **a, b,** but for γ2-C and β3-B subunits. **e, f,** the same as **a, b,** but for β3-B and α1-A subunits. Amino acid residues present in β1-β2 loop tip in each subunit are shown, the C~α~s for these residues are represented as spheres and the distances of displacement indicated. The strictly conserved M2-M3 loop proline residue interacting with the β1-β2 loop is shown for each subunit. β1-β2 loop motions are indicated by curved arrows. **g-l**, Conformational differences in the M2-M3 loop and 19\' Arg side chain positions between the PTX- and the ALP/GABA-bound structures shown for α-A (g, h), g2-C (i, j) and b3-B (k, l) subunits. Neighbouring subunit M1 and M2 helices are shown as cylinders. Dashed lines indicate putative hydrogen bond interactions between amino acid side chains and mainchain carbonyls.](emss-80639-f013){#F13}

###### Cryo-EM data collection, refinement and validation statistics.

\*Local resolution range. ^Ψ^Resolution at which FSC between map and model is 0.5.

  ------------------------------------------------------------------------------------------------------------------------
                                       PTX            PTX/GABA       BCC               ALP/GABA          DZP/GABA
  ------------------------------------ -------------- -------------- ----------------- ----------------- -----------------
  **Data collection and processing**                                                                     

  Microscope, location                 Krios-S,\      Krios-II,\     Krios-II, MRC-\   Krios-II, MRC-\   Krios-I, MRC-\
                                       STRUBI         MRC-LMB        LMB               LMB               LMB

  Magnification                        75,000         75,000         75,000            75,000            130,000

  Voltage (kV)                         300            300            300               300               300

  Detector                             Falcon 3EC\    Falcon 3EC\    Falcon 3EC        Falcon 3EC\       K2 Summit with\
                                       with VPP       with VPP                         with VPP          GIF

  Pixel size (Å)                       1.055          1.07           1.07              1.07              0.89

  Electron exposure (e--/Å^2^)         30             30             30                30                62

  Exposure length (s)                  60             60             60                60                14

  Dose rate (e--/pixel/s)              0.5            0.55           0.55              0.55              4.5

  Frame number                         75             75             75                75                40

  Defocus range (μm)                   -0.7 to -0.5   -0.7 to -0.5   -0.7 to -0.5      -0.7 to -0.5      -3.6 to -2.4

  Micrographs collected (no.)          803            794            988               815               768

  Micrographs selected (no.)           664            659            964               617               593

  Initial particle images (no.)        205,673        292,669        489,434           210,073           233,543

  Final particle images (no.)          56,269         67,604         30,536            39,050            55077

  Symmetry imposed                     C1             C1             C1                C1                C1

  Map resolution (Å)                   3.10           3.04           3.69              3.26              3.58

      FSC threshold                    0.143          0.143          0.143             0.143             0.143

  Map resolution range (Å)\*           2.6-6.0        2.6-6.0        2.4-6.0           2.7-6.0           2.4-6.0

  **Refinement**                                                                                         

  Initial model used (PDB code)        N/A            N/A            N/A               N/A               N/A

  Model resolution (Å^2^)              3.15           3.13           3.75              3.34              3.66

              FSC threshold            0.5            0.5            0.5               0.5               0.5

  Model resolution range (Å)^Ψ^        3.15           3.13           3.75              3.34              3.66

  Map sharpening *B* factor (Å^2^)     -73            -82            -128              -79               -119

  Model composition                                                                                      

      Protein residues                 1,817          1,814          1,817             1,810             1,810

      Non-hydrogen atoms               15,297         15,263         15,308            15,235            15,273

      Protein atoms                    14,788         14,763         14,788            14,733            14,733

      N-linked glycan atoms            394            372            372               372               372

      PTX atoms                        21             21             \-                \-                \-

      GABA atoms                       \-             14             \-                14                14

      BCC atoms                        \-             \-             54                \-                \-

      ALP atoms                        \-             \-             \-                22                \-

      DZP atoms                        \-             \-             \-                \-                60

      PIP2 atoms                       94             94             94                94                94

  R.m.s. deviations                                                                                      

      Bond lengths (Å)                 0.005          0.005          0.009             0.005             0.013

      Bond angles (°)                  0.81           0.79           0.78              0.81              1.11

  Validation                                                                                             

      MolProbity score                 1.45           1.50           1.53              1.50              1.66

      Clashscore                       4.64           4.55           4.97              4.66              5.86

      Poor rotamers (%)                0              0              0                 0                 0

  Ramachandran plot                                                                                      

      Favored (%)                      96.65          96.03          96.04             96.19             95.07

      Allowed (%)                      3.35           3.97           3.96              3.81              4.93

      Disallowed (%)                   0              0              0                 0                 0
  ------------------------------------------------------------------------------------------------------------------------

###### Analysis of interfaces between α1β3γ2L GABA~A~R subunits.

\*Buried surface area per interface (sum of monomer areas buried at the interface, divided by 2, calculated using PDBePISA[@R67]). ^†^ΔiG (solvation energy gain at complex formation) is the change of the solvation energy of a subunit due to interface formation, in kcal/mol, calculated using PDBePISA[@R67]).

                     Subunit interface   Interface area\* (Å^2^)   ΔiG^†^ (kcal/mol)                           
  ------------------ ------------------- ------------------------- ------------------- ------- ------- ------- -------
  PTX                α1-A^+^/ β3-E^−^    1536                      1182                2797    -11.5   -23.7   -35.7
  β3-E^+^/ α1-D^−^   1246                1583                      2905                -12.3   -30.4   -43.8   
  α1-D^+^/ γ2-C^−^   1400                1229                      2781                -5.8    -25.2   -32.3   
  γ2-C^+^/ β3-B^−^   1619                1203                      2895                -13.7   -20.4   -34.7   
  β3-B^+^/ α1-A^−^   1251                1652                      2990                -13.3   -31.1   -45.7   
  Mb38/ α1-A         810                 \-                        829                 -6.0    \-      -6.1    
  Mb38/ β3-E         232                 \-                        232                 -2.1    \-      -2.1    
  PTX/GABA           α1-A^+^/ β3-E^−^    1534                      1224                2856    -11.9   -24.8   -35.8
  β3-E^+^/ α1-D^−^   1480                1534                      3113                -13.2   -28.9   -43.6   
  α1-D^+^/ γ2-C^−^   1423                1221                      2781                -6.4    -25.0   -32.4   
  γ2-C^+^/ β3-B^−^   1618                1204                      2911                -13.8   -21.6   -36.5   
  β3-B^+^/ α1-A^−^   1435                1618                      3166                -14.5   -29.8   -45.9   
  Mb38/ α1-A         822                 \-                        834                 -7.0    \-      -7.1    
  Mb38/ β3-E         248                 \-                        248                 -2.3    \-      -2.3    
  BCC                α1-A^+^/ β3-E^−^    1531                      1180                2810    -10.5   -24.5   -36.1
  β3-E^+^/ α1-D^−^   1309                1555                      2982                -14.0   -29.4   -44.4   
  α1-D^+^/ γ2-C^−^   1426                1155                      2737                -7.9    -23.4   -32.6   
  γ2-C^+^/ β3-B^−^   1589                1214                      2894                -12.7   -21.1   -34.9   
  β3-B^+^/ α1-A^−^   1319                1602                      3043                -11.8   -30.0   -43.7   
  Mb38 / α1-A        815                 \-                        830                 -6.2    \-      -6.3    
  Mb38 / γ3-E        248                 \-                        248                 -2.9    \-      -2.9    
  GABA/ALP           α1-A^+^/ β3-E^−^    1563                      1167                2833    -11.8   -23.3   -35.8
  β3-E^+^/ α1-D^−^   1501                1353                      2960                -13.8   -24.0   -39.9   
  α1-D^+^/ γ2-C^−^   1346                1051                      2512                -5.6    -19.5   -25.1   
  γ2-C^+^/ β3-B^−^   1620                1220                      2937                -11.9   -22.0   -34.4   
  β3-B^+^/ α1-A^−^   1510                1415                      3034                -14.4   -25.8   -40.9   
  Mb38 / α1-A        834                 \-                        834                 -5.8    \-      -5.9    
  Mb38 / β3-E        238                 \-                        238                 -2.6    \-      -2.6    
  GABA/DZP           α1-A^+^/ β3-E^−^    1527                      1103                2733    -11.2   -24.0   -36.4
  β3-E^+^/ α1-D^−^   1453                1273                      2838                -13.3   -22.1   -37.0   
  α1-D^+^/ γ2-C^−^   1324                1063                      2505                -4.1    -23.5   -28.4   
  γ2-C^+^/ β3-B^−^   1564                1168                      2846                -13.2   -19.7   -33.3   
  β3-B^+^/ α1-A^−^   1473                1377                      2955                -12.9   -23.3   -37.1   
  Mb38 / α1-A        794                 \-                        800                 -5.5    \-      -5.7    
  Mb38 / β3-E        231                 \-                        231                 -2.4    \-      -2.4    
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![Structure of the α1β3γ2L GABA~A~R in complex with picrotoxin (PTX).\
**a,** Cryo-EM map of the PTX-bound α1β3γ2L GABA~A~R viewed from the extracellular space (left) and parallel to the membrane plane (right). PTX binding site is boxed. **b**, **c**, Side-on (**b**) and top-down views (**c**) of PTX (carbon atoms in pink, oxygen atoms in red) bound to the channel pore, with the amino acid side chains lining the site shown as sticks. Dashed lines indicate hydrogen bonds.](emss-80639-f001){#F1}

![Conformational impact of GABA binding to the α1β3γ2L GABA~A~R.\
**a**, Cryo-EM map of the PTX/GABA-bound α1β3γ2L receptor viewed from the extracellular space (left) and parallel to the membrane plane (right). **b**, One GABA (balls and sticks; carbon atoms, khaki; oxygens, red; nitrogen, blue) binding pocket viewed from the extracellular space. **c**, Plot of the pore radii for the receptor bound to PTX and PTX/GABA. **d,** Superimposition of ECDs from the PTX- (grey) and PTX/GABA-bound receptor structures based on the global TMD alignment. Subunits were radially translated away by 10 Å from the pore axis to allow better visualisation of conformational changes in the ECD upon GABA binding. GABA-induced ECD rotation is defined as angles of rotation around the ECD rotation axes and the direction of motion are shown. **e**, **f,** Superimposition of α1 ECDs from PTX-bound and PTX/GABA-bound structures reveals conformational changes induced by GABA binding in the orthosteric pockets at β3-B^+^/α1-A^--^ (**e**) and β3-E^+^/α1-D^--^ interfaces (**f**). Dashed lines indicate hydrogen bonds, π-π stacking, π-cation interactions and salt bridges.](emss-80639-f002){#F2}

![Structure of a α1β3γ2L GABA~A~R closed by the competitive antagonist bicuculline.\
**a-c,** Representative whole-cell current traces elicited from the same cell (n = 4) by a 42s pulse of: Mb38 alone (**a**); Mb38 plus bicuculline (BCC) co-applied for 13s at 25s mark (**b**); Mb38 again, after BCC was washed out (**c**). **d**, Cryo-EM map of the α1β3γ2 GABA~A~R-BCC complex viewed parallel to the membrane plane. **e,** One BCC binding pocket at the β3^+^/α1^--^ interface, viewed parallel to the membrane. Dashed lines indicate π-π interactions and hydrogen bonds. **f,** Plot of the pore radii for the α1β3γ2 receptor bound to PTX or BCC.](emss-80639-f003){#F3}

![Structures of a α1β3γ2L GABA~A~R in desensitised states induced by GABA and alprazolam/diazepam.\
**a,** Structural formulae of diazepam and alprazolam. Diazepine ring atoms are numbered. Imidazole (I) and benzene rings (A) are labelled. **b,c**, The cryo-EM map of the α1β3γ2 GABA~A~R in complex with ALP (cyan) (**b**) and DZP (teal) (**c**) viewed parallel to the membrane plane. **d,e**, Views of the benzodiazepine binding site at the α1^+^/γ2^--^ interface showing ALP (**d**) and DZP (**e**) binding modes. Dashed lines indicate π-π interactions and hydrogen bonds. **f**, The low affinity DZP binding site in the β3^+^/α1^--^ interface TMD region. **g**, Plot of the pore radii for the receptor bound to PTX, ALP/GABA and DZP/GABA. **h**, Representative current traces evoked by co-application of GABA (10 mM) with Mb38 (2 μM) and DZP (100 μM) for 40s to outside-out patches pulled from HEK cells. The currents (n = 6 patches) desensitized completely in three phases; a slow (0.78± 0.84 s^-1^); medium (16.32 ± 9.34 s^-1^), and a fast (306.5± 185.9 s^-1^) rates. Rate values are mean ± S.D. The upper black solid bar shows the duration of ligand application.](emss-80639-f004){#F4}

![Conformational differences between closed-resting and desensitised states in a GABA~A~ receptor.\
**a,** Superimposition of ECDs from PTX (grey) and ALP/GABA structures based on the global TMD alignment. Subunits were radially translated by 10 Å away from the pore axis to allow better visualisation of conformational changes in the ECD upon GABA and ALP binding. GABA- and ALP-induced ECD rotation angles, around the rotational ECD axes, and the direction of motion are shown. **b,** Global TMD alignment for the PTX- (grey) and ALP/GABA-bound (coloured) structures. 9\' Leu side chains are shown as sticks. **c,** Schematic illustration of conformational changes initiated by GABA binding at the extracellular domain (ECD) level. GABA stabilizes closure of loop-C in each β subunit, causing ECDs to rotate and form stronger β3^+^/α1^--^ interfaces. The direction and magnitude of rotation are depicted as black arrows of varying thickness. BZDs such as alprazolam bind at the α1^+^/γ2^--^ interface and reinforce it, facilitating the concerted rotation of the ECDs. Black bars ("stitches") at the subunit interfaces represent the strength of the interfaces (See [Extended Data Table 2](#T2){ref-type="table"}.). **d,** Differences in the ECD-TMD relative orientations between the closed/resting and desensitised states illustrate how GABA binding and ECD rotation impact on transmembrane domains (TMDs). Notably, the M2-M3 loops in β subunits deform more than α and γ equivalents, resulting in lower degrees of M2 tilt and TMD rotation.](emss-80639-f005){#F5}
